Bristol-Myers Squibb Co vs Five9 Inc — how do they compare? Bristol-Myers Squibb Co trades at $64.7 (market cap $130.12B), while Five9 Inc trades at $33.74 (market cap $2.33B). The key difference: Bristol-Myers Squibb Co is far larger — about 55.8× Five9 Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Five9 Inc pays none. Which is the better fit depends on your goals.
| BMY | FIVN | |
|---|---|---|
Market Cap | $130.12B | $2.33B |
Sector | Health | Technology |
52-Week High | $65.89 | $34.48 |
52-Week Low | $42.60 | $13.61 |
Enterprise Value | $164.11B | $2.48B |
Dividend Yield | 3.96% | — |
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →